☰

Carl E. Ruby, Ph.D. - Publications

Affiliations: 
2002 Oregon State University, Corvallis, OR 
Area:
Cell Biology, Environmental Sciences, Molecular Biology, Toxicology
Tree Info Grants Similar researchers PubMed Report error

23 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2017 Troyer RM, Ruby CE, Goodall CP, Yang L, Maier CS, Albarqi HA, Brady JV, Bathke K, Taratula O, Mourich D, Bracha S. Exosomes from Osteosarcoma and normal osteoblast differ in proteomic cargo and immunomodulatory effects on T cells. Experimental Cell Research. PMID 28712929 DOI: 10.1016/J.Yexcr.2017.07.011  0.479
2015 Kohlhapp FJ, Broucek JR, Hughes T, Huelsmann EJ, Lusciks J, Zayas JP, Dolubizno H, Fleetwood VA, Grin A, Hill GE, Poshepny JL, Nabatiyan A, Ruby CE, Snook JD, Rudra JS, et al. NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade. Journal For Immunotherapy of Cancer. 3: 18. PMID 25992289 DOI: 10.1186/S40425-015-0063-3  0.327
2014 Kaufman HL, Ruby CE, Hughes T, Slingluff CL. Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma. Journal For Immunotherapy of Cancer. 2: 11. PMID 24971166 DOI: 10.1186/2051-1426-2-11  0.318
2014 Kim DW, Zloza A, Broucek J, Schenkel JM, Ruby C, Samaha G, Kaufman HL. Interleukin-2 alters distribution of CD144 (VE-cadherin) in endothelial cells. Journal of Translational Medicine. 12: 113. PMID 24885155 DOI: 10.1186/1479-5876-12-113  0.314
2014 Farazi M, Cohn Z, Nguyen J, Weinberg AD, Ruby CE. Early-onset age-related changes in dendritic cell subsets can impair antigen-specific T helper 1 (Th1) CD4 T cell priming. Journal of Leukocyte Biology. 96: 245-54. PMID 24714553 DOI: 10.1189/jlb.1A0114-066R  0.557
2014 Farazi M, Nguyen J, Goldufsky J, Linnane S, Lukaesko L, Weinberg AD, Ruby CE. Caloric restriction maintains OX40 agonist-mediated tumor immunity and CD4 T cell priming during aging. Cancer Immunology, Immunotherapy : Cii. 63: 615-26. PMID 24682539 DOI: 10.1007/s00262-014-1542-y  0.446
2014 Broucek J, Hughes T, Huelsmann E, Lusciks E, Hill G, Zayas J, Poshepny J, Ruby C, Kohlhapp F, Zloza A, Kaufman H. Combination immunotherapy with anti-CTLA-4 and interleukin-2 redirects regulatory T cells into tumor-draining lymph nodes and expands anti-tumor CD8+ T cells in the tumor microenvironment Journal For Immunotherapy of Cancer. 2. DOI: 10.1186/2051-1426-2-S3-P97  0.328
2013 Stonewall K, Quintero C, Zloza A, Kaufman H, Ruby C. The impact of age on a mitoxantrone-based tumor vaccine Journal For Immunotherapy of Cancer. 1: P234. DOI: 10.1186/2051-1426-1-S1-P234  0.363
2011 Vasilevsky NA, Ruby CE, Hurlin PJ, Weinberg AD. OX40 engagement stabilizes Mxd4 and Mnt protein levels in antigen-stimulated T cells leading to an increase in cell survival. European Journal of Immunology. 41: 1024-34. PMID 21400495 DOI: 10.1002/eji.201040449  0.434
2010 Jensen SM, Maston LD, Gough MJ, Ruby CE, Redmond WL, Crittenden M, Li Y, Puri S, Poehlein CH, Morris N, Kovacsovics-Bankowski M, Moudgil T, Twitty C, Walker EB, Hu HM, et al. Signaling through OX40 enhances antitumor immunity. Seminars in Oncology. 37: 524-32. PMID 21074068 DOI: 10.1053/j.seminoncol.2010.09.013  0.344
2009 Ruby CE, Yates MA, Hirschhorn-Cymerman D, Chlebeck P, Wolchok JD, Houghton AN, Offner H, Weinberg AD. Cutting Edge: OX40 agonists can drive regulatory T cell expansion if the cytokine milieu is right. Journal of Immunology (Baltimore, Md. : 1950). 183: 4853-7. PMID 19786544 DOI: 10.4049/Jimmunol.0901112  0.505
2009 Redmond WL, Ruby CE, Weinberg AD. The role of OX40-mediated co-stimulation in T-cell activation and survival. Critical Reviews in Immunology. 29: 187-201. PMID 19538134  0.534
2009 Ruby CE, Weinberg AD. The effect of aging on OX40 agonist-mediated cancer immunotherapy. Cancer Immunology, Immunotherapy : Cii. 58: 1941-7. PMID 19288101 DOI: 10.1007/s00262-009-0687-6  0.406
2009 Ruby CE, Weinberg AD. OX40-enhanced tumor rejection and effector T cell differentiation decreases with age. Journal of Immunology (Baltimore, Md. : 1950). 182: 1481-9. PMID 19155495  0.326
2009 Ruby CE, Weinberg AD. Manipulating TNF receptors to enhance tumor immunity for the treatment of cancer Targeted Cancer Immune Therapy. 319-336. DOI: 10.1007/978-1-4419-0170-5_18  0.53
2008 Gough MJ, Ruby CE, Redmond WL, Dhungel B, Brown A, Weinberg AD. OX40 agonist therapy enhances CD8 infiltration and decreases immune suppression in the tumor. Cancer Research. 68: 5206-15. PMID 18593921 DOI: 10.1158/0008-5472.CAN-07-6484  0.44
2008 Ruby CE, Montler R, Zheng R, Shu S, Weinberg AD. IL-12 is required for anti-OX40-mediated CD4 T cell survival Journal of Immunology. 180: 2140-2148. PMID 18250420  0.44
2007 Ruby CE, Redmond WL, Haley D, Weinberg AD. Anti-OX40 stimulation in vivo enhances CD8+ memory T cell survival and significantly increases recall responses European Journal of Immunology. 37: 157-166. PMID 17183611 DOI: 10.1002/eji.200636428  0.539
2006 Maxwell JR, Yadav R, Rossi RJ, Ruby CE, Weinberg AD, Aguila HL, Vella AT. IL-18 bridges innate and adaptive immunity through IFN-gamma and the CD134 pathway. Journal of Immunology (Baltimore, Md. : 1950). 177: 234-45. PMID 16785519 DOI: 10.4049/Jimmunol.177.1.234  0.43
2005 Ruby CE, Funatake CJ, Kerkvliet NI. 2,3,7,8 Tetrachlorodibenzo-p-Dioxin (TCDD) Directly Enhances the Maturation and Apoptosis of Dendritic Cells In Vitro. Journal of Immunotoxicology. 1: 159-66. PMID 18958649 DOI: 10.1080/15476910490920968  0.604
2005 Ruby CE, Funatake CJ, Kerkvliet NI. 2,3,7,8 tetrachlorodibenzo-p-dioxin (TCDD) directly enhances the maturation and apoptosis of dendritic cells in vitro Journal of Immunotoxicology. 1: 159-166. DOI: 10.1080/15476910490920968  0.604
2002 Ruby CE, Leid M, Kerkvliet NI. 2,3,7,8-Tetrachlorodibenzo-p-dioxin suppresses tumor necrosis factor-α and anti-CD40-induced activation of NF-κB/Rel in dendritic cells: p50 homodimer activation is not affected Molecular Pharmacology. 62: 722-728. PMID 12181450 DOI: 10.1124/Mol.62.3.722  0.685
2002 Maxwell JR, Ruby C, Kerkvliet NI, Vella AT. Contrasting the roles of costimulation and the natural adjuvant lipopolysaccharide during the induction of T cell immunity. Journal of Immunology (Baltimore, Md. : 1950). 168: 4372-81. PMID 11970979 DOI: 10.4049/Jimmunol.168.9.4372  0.645
Show low-probability matches.